Login / Signup

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors.

Evelina MieleLuana AbballeGian Paolo SpinelliZein Mersini BesharatGiuseppina CatanzaroMartina ChiacchiariniAlessandra VaccaAgnese PoCarlo CapalboElisabetta Ferretti
Published in: BMC cancer (2020)
Our findings support the importance of ErbB2 evaluation in BRAF-mutated CRC patients and its role as a positive predictor factor of response to BRAFi/ErbBi combination.
Keyphrases
  • wild type
  • tyrosine kinase
  • end stage renal disease
  • metastatic colorectal cancer
  • ejection fraction
  • newly diagnosed
  • poor prognosis
  • prognostic factors
  • peritoneal dialysis
  • long non coding rna